Mutations of the BRAF gene in human cancer H Davies, GR Bignell, C Cox, P Stephens, S Edkins, S Clegg, J Teague, ... Nature 417 (6892), 949-954, 2002 | 12685 | 2002 |
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF PTC Wan, MJ Garnett, SM Roe, S Lee, D Niculescu-Duvaz, VM Good, ... Cell 116 (6), 855-867, 2004 | 3277 | 2004 |
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells W Yang, J Soares, P Greninger, EJ Edelman, H Lightfoot, S Forbes, ... Nucleic acids research 41 (D1), D955-D961, 2012 | 2896 | 2012 |
Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2551 | 2012 |
Prospective derivation of a living organoid biobank of colorectal cancer patients M Van de Wetering, HE Francies, JM Francis, G Bounova, F Iorio, A Pronk, ... Cell 161 (4), 933-945, 2015 | 2072 | 2015 |
A landscape of pharmacogenomic interactions in cancer F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ... Cell 166 (3), 740-754, 2016 | 1728 | 2016 |
Guilty as charged: B-RAF is a human oncogene MJ Garnett, R Marais Cancer cell 6 (4), 313-319, 2004 | 1166 | 2004 |
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening L Broutier, G Mastrogiovanni, MMA Verstegen, HE Francies, LM Gavarró, ... Nature medicine 23 (12), 1424-1435, 2017 | 1131 | 2017 |
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019 | 1021 | 2019 |
Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties MP Menden, F Iorio, M Garnett, U McDermott, CH Benes, PJ Ballester, ... PLoS one 8 (4), e61318, 2013 | 534 | 2013 |
The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 529 | 2018 |
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization MJ Garnett, S Rana, H Paterson, D Barford, R Marais Molecular cell 20 (6), 963-969, 2005 | 507 | 2005 |
Perturbation-response genes reveal signaling footprints in cancer gene expression M Schubert, B Klinger, M Klünemann, A Sieber, F Uhlitz, S Sauer, ... Nature communications 9 (1), 20, 2018 | 487 | 2018 |
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling S Huang, M Hölzel, T Knijnenburg, A Schlicker, P Roepman, U McDermott, ... Cell 151 (5), 937-950, 2012 | 479 | 2012 |
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ... Cell 167 (1), 260-274. e22, 2016 | 446 | 2016 |
ETV6-NTRK3 Gene Fusions and Trisomy 11 Establish a Histogenetic Link between Mesoblastic Nephroma and Congenital Fibrosarcoma SR Knezevich, MJ Garnett, TJ Pysher, JB Beckwith, PE Grundy, ... Cancer research 58 (22), 5046-5048, 1998 | 421 | 1998 |
Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis M Petljak, LB Alexandrov, JS Brammeld, S Price, DC Wedge, ... Cell 176 (6), 1282-1294. e20, 2019 | 350 | 2019 |
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening E Driehuis, A Van Hoeck, K Moore, S Kolders, HE Francies, ... Proceedings of the National Academy of Sciences 116 (52), 26580-26590, 2019 | 335 | 2019 |
High-content CRISPR screening C Bock, P Datlinger, F Chardon, MA Coelho, MB Dong, KA Lawson, T Lu, ... Nature Reviews Methods Primers 2 (1), 1-23, 2022 | 295 | 2022 |
UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit MJ Garnett, J Mansfeld, C Godwin, T Matsusaka, J Wu, P Russell, J Pines, ... Nature cell biology 11 (11), 1363-1369, 2009 | 294 | 2009 |